Even though measuring Ang-2 serum levels would be a practicable non-invasive method to assess the risk of lymph node metastases in early ovarian cancer, it has to be taken into account that Ang-2 serum expression levels are also affected by other pathologies. This evidence concerns the gene ANGPT2 and ovarian carcinoma.